Cardiovascular Profile and Role of Extracorporeal Membrane Oxygenation (ECMO) in Patients with Aluminium Phosphide Poisoning: A Prospective Observational Study
Background: Aluminium phosphide (ALP) poisoning is a significant cause of morbidity and mortality in developing countries due to its widespread use as an agricultural fumigant and lack of a specific antidote. The toxicity of phosphine gas released after ingestion primarily affects the cardiovascular system, leading to myocardial depression, refractory hypotension, and life-threatening arrhythmias. Advanced supportive measures such as extracorporeal membrane oxygenation (ECMO) have recently been used in severe cases with cardiogenic shock. This study aimed to evaluate the cardiovascular manifestations, clinical outcomes, and the role of ECMO in patients with aluminium phosphide poisoning. Methods: This prospective observational study was conducted in the Department of Medicine and Intensive Care Unit at Geetanjali Medical College and Hospital (GMCH), Udaipur, over a period of six months. A total of 50 patients with confirmed aluminium phosphide poisoning were included. Demographic characteristics, hemodynamic parameters, electrocardiographic findings, echocardiographic assessment, arterial blood gas analysis, laboratory investigations, and treatment modalities including ECMO were recorded. Left ventricular ejection fraction (LVEF) was assessed at admission and discharge. Patients were followed during hospitalization to determine clinical outcomes. Results: The mean age of patients was 33.39 ± 11.72 years with a slight male predominance. The overall mortality rate was 36%. Patients commonly presented with hypotension and tachycardia. Significant myocardial depression was observed at admission with markedly reduced LVEF, which improved significantly at discharge among survivors. Ventricular tachycardia and ventricular fibrillation were the most common arrhythmias. Significant differences in arterial blood gas parameters, including pH, PaCO₂, PaO₂, and lactate levels, were observed between survivors and non-survivors. Laboratory parameters demonstrated significant changes in lactate, hemoglobin, liver enzymes, and electrolytes during hospitalization. ECMO support was required in patients with severe cardiogenic shock and refractory circulatory failure. Conclusion: Cardiovascular dysfunction is a major determinant of outcome in aluminium phosphide poisoning. Early recognition of myocardial depression, metabolic abnormalities, and arrhythmias, along with advanced supportive therapies such as ECMO in selected patients, may improve survival in severe cases.